The decisions made at the Greater Manchester Medicines Management Group (GMMMG) July 2025 meeting and August 2025 virtual meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary and RAG list
- Budesonide 4mg suppositories – green (specialist advice)
- Fenfluramine for Lennox-Gastaut syndrome – red
- Pregabalin modified-release tablets – Do Not Prescribe
- Molnupiravir for COVID-19 – red, only in line with commissioned CMDU arrangements
- Nirmatrelvir plus ritonavir – red, only in line with updated NICE guidance
- Interim Alignment of Eligibility Criteria for GLP-1 Receptor Agonists (GLP-1 RAs) in Weight Management in GM
- Efanesoctocog alfa for haemophilia A – red
- Cladribine for active relapsing MS – red
- Ruxolitinib for GvHD – red
- Leniolisib for activated phosphoinositide 3-kinase delta syndrome – red
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
The following are available at https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/.
- GMMMG high cost drug pathways for ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis
- Greater Manchester Secondary Prevention Lipid Pathway
- GMMMG Commissioning Statement: Inclisiran▼ for treating primary hypercholesterolaemia or mixed dyslipidaemia
The following is available at https://gmmmg.nhs.uk/joint-formulary/submissions/.
- Updated grey list criteria
For full details of new and updated pathways, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.